Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02460705 · ClinicalTrials.gov registry record · Early Phase 1
Fecal Microbiota Transplant for Inflammatory Bowel Disease
A Early Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 59
- Enrollment target
NCT02460705: Completed Early Phase 1 study, sponsored by University of California, San Francisco.
NCT02460705 is a Early Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 59 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02460705, a Early Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
Currently enrolling only patients with Ulcerative Colitis. Enrollment and experimental treatment of patients with Crohn's Disease stopped for a safety evaluation. This is a prospective, open label pilot study in which patients with symptoms of Inflammatory bowel disease will receive FMT therapy delivered via colonoscopy. The investigators hypothesize that FMT is a safe and effective treatment for patients with inflammatory bowel disease. The aims are: 1. To determine if symptoms of inflammatory bowel disease can be successfully treated by Fecal Microbial Transplantation. 2. To determine if endoscopic appearance of colon or ileum improves following treatment by Fecal Microbial Transplantation.
Primary Outcome
In order to assess clinical improvement of IBD, patients will be scheduled for a 4 week post-FMT treatment clinic visit to assess patient symptoms.
Interventions
- DRUG Biologically active human fecal material, OpenBiome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-11-04 |
| Phase | Early Phase 1 |
What the finished NCT02460705 record still lists
NCT02460705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 1 intervention - of which Biologically active human fecal material, OpenBiome is the first listed.
NCT02460705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02460705 about?
NCT02460705 is a clinical study titled "Fecal Microbiota Transplant for Inflammatory Bowel Disease". Currently enrolling only patients with Ulcerative Colitis. Enrollment and experimental treatment of patients with Crohn's Disease stopped for a safety evaluation. This is a prospective, open label pilot study in which patients with symptoms of Inflammatory bowel disease will receive FMT therapy del...
What is the current status of trial NCT02460705?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 59 participants. The study started on 2015-06. Estimated completion is 2017-11-04.
What interventions are being tested in trial NCT02460705?
The interventions under investigation include: Biologically active human fecal material, OpenBiome (DRUG).
Who is sponsoring clinical trial NCT02460705?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02460705's enrollment target sits among peer trials
59 437th of 2000 higher than 1,561 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia